4167 | 松瑞藥 - Stock Value & PE Ratio Analysis

3

24

15

Excellent Growth

AI analysis rates 4167 with the highest value score of 5.
It is mainly due to stable revenue growth, along with adequate operating cash flow.
Over the past 3 months, 4167 has maintained a consecutive value rating of 5.0, slightly higher than the rating of 4.4 over the past 3 years, indicating continued upward trend in enterprise value.
Compared to all stocks in the Biotech. & Medical sector, 4167 has a higher value rating.

4167 Value Reference Factors

The Value score is derived from various data and factor information, integrated through AI algorithms. The following factors are part of the evaluation used by AI value scores.

Update to 2025/03/21 (Weekly Update)

4167 Financial Forecast

Unit : TWD

Update to 2025/5/9 (Quarterly Update)

4167 Earnings Table

Unit : TWD

QTR	Non-GAAP EPS	EPS YoY	EPS Surprise %	Sales	Sales YoY	Sales Surprise %	NPM
Current	0.15	7.1%	-	276.94M	-12.9%	-	16.5%
2024Q3	0.13	360%	-	332.46M	15.7%	-	12.6%
2024Q2	0.07	250%	-	348.73M	56.3%	-	6%
2024Q1	0.22	2,300%	-	259.19M	16.8%	-	26.9%
2023Q4	0.14	207.7%	-	317.98M	25.1%	-	13.6%

Update to 2025/5/10 (Quarterly Update)

4167 Historical Value Score

You can use historical scores of 3 or above to observe potential performance and make investment decisions.

4167 Value Strategy Backtest

The following backtest is based on specified rules since 2007. Price chart shows buy/sell time, cumulative returns, and backtesting statistics.

Entry

Exit

The Backtest Result of 4167 from 2015/09 till Now

17.20%
Cumulative Return: 1.71%
Annual Return: 31.43%
Volatility: 0.05
Sharpe Ratio

Statistics data for entering at or above a Value score of 4 and exiting at or below a Value score of 2 from September, 2015 to May, 2025. (Total Trades: 1)